Amphix Bio | $12,500,000 | (Dec 19, 2025)
arcads AI | $16,000,000 | (Dec 19, 2025)
Katalist | $1,500,000 | (Dec 19, 2025)
Certified by Founder
Lodge
DiogenX
start up
France
- Marseille
- 11/05/2023
- Series A
- $30,056,125
DiogenX is a preclinical stage biotech company committed to a single mission: to discover and develop innovative biologics as new therapeutics options for millions of Diabetic patients around the world.
Our lead program, originating from Dr Patrick Collombat’s laboratory, is based on a new approach targeting beta-cell failure throughout the stimulation of beta-cell functional recovery in diabetes. This novel mode of action will provide a unique solution to rebalance glucose/insulin homeostasis and thus offer clear clinically meaningful benefits.
DiogenX is headquartered in Marseille, with labs in Nice (France).
- Industry Biotechnology
- Website https://diogenx.com/
- LinkedIn https://www.linkedin.com/company/diogenx/
Syremis Therapeutics | $165,000,000 | (Dec 19, 2025)
Gravity Labs Co., Ltd. | $17,000,000 | (Dec 19, 2025)
Edison Scientific | $70,000,000 | (Dec 19, 2025)
InfiniteWatch | $4,000,000 | (Dec 19, 2025)
Thread | $18,000,000 | (Dec 19, 2025)
Neural Concept | $100,000,000 | (Dec 19, 2025)
SkillCorner | $60,000,000 | (Dec 19, 2025)
Wearlinq | $14,000,000 | (Dec 18, 2025)
T-CURX GmbH | $20,000,000 | (Dec 18, 2025)